Advertisement
Singapore markets close in 35 minutes

  • Straits Times Index

    3,277.45
    -10.30 (-0.31%)
     

  • Nikkei

    37,934.76
    +306.28 (+0.81%)
     

  • Hang Seng

    17,651.15
    +366.61 (+2.12%)
     

  • FTSE 100

    8,119.08
    +40.22 (+0.50%)
     

  • Bitcoin USD

    64,399.04
    +319.25 (+0.50%)
     

  • CMC Crypto 200

    1,389.34
    -7.20 (-0.52%)
     

  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     

  • Dow

    38,085.80
    -375.12 (-0.98%)
     

  • Nasdaq

    15,611.76
    -100.99 (-0.64%)
     

  • Gold

    2,359.00
    +16.50 (+0.70%)
     

  • Crude Oil

    83.85
    +0.28 (+0.34%)
     

  • 10-Yr Bond

    4.7060
    +0.0540 (+1.16%)
     

  • FTSE Bursa Malaysia

    1,573.71
    +4.46 (+0.28%)
     

  • Jakarta Composite Index

    7,049.19
    -106.11 (-1.48%)
     

  • PSE Index

    6,628.75
    +53.87 (+0.82%)
     

Blueprint Medicines: 3Q Earnings Snapshot

Blueprint Medicines: 3Q Earnings Snapshot

Associated Press

CAMBRIDGE, Mass. (AP) _ Blueprint Medicines Corp. (BPMC) on Tuesday reported a loss of $72.7 million in its third quarter.

The Cambridge, Massachusetts-based company said it had a loss of $1.66 per share.

The results missed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of $1.57 per share.

The cancer drug developer posted revenue of $1.1 million in the period, which also fell short of Street forecasts. Four analysts surveyed by Zacks expected $2 million.

Blueprint Medicines shares have fallen 18 percent since the beginning of the year. The stock has fallen 12 percent in the last 12 months.

_____

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on BPMC at https://www.zacks.com/ap/BPMC